Swedish Startup Mulls Listing in AbbVie Parkinson’s Challenge
- Lobsor’s Lecigon approved by Swedish Medical Products Agency
- Startup now considering IPO, other options, to fund rollout
This article is for subscribers only.
Lobsor Pharmaceuticals AB is considering an initial public offering to supercharge European expansion after its Parkinson’s treatment was just approved by the Swedish Medical Products Agency.
The Swedish startup is reviewing options, which include selling shares on Stockholm’s First North Premium marketplace, Chairman Ulf Rosen said in an interview in Stockholm. Uppsala-based Lobsor could also turn to private equity for funding or finance an expansion using its own funds and expected revenue from the Nordic region. It plans to decide on a path in the spring, he said.